Amylyx Pharmaceuticals Publishes Presentation on Phase 3 Avexitide Trial Results

• Amylyx Pharmaceuticals published a presentation reporting Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia.
• Avexitide reduced composite level 2/3 hypoglycemic event rates by 55% versus placebo, meeting the primary endpoint (p=0.0000034).
• All prespecified, multiplicity-controlled secondary endpoints were met, with hypoglycemic event reductions ranging from 42% to 63% versus placebo.
• Adverse events were primarily gastrointestinal or injection-site reactions, generally mild to moderate; treatment discontinuations occurred in 4% versus 3% with placebo.
• Body weight and fasting plasma glucose showed no clinically meaningful changes through Week 16.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief on November 14, 2026, and is solely responsible for the information contained therein.